Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience

BACKGROUND: Thymic carcinoma (TC) is a rare aggressive tumour. Median survival with current treatments is only 2 years. Sunitinib is a multi-targeted tyrosine kinase inhibitor that has shown benefit in various other cancers. METHODS: Laboratory analyses of snap-frozen tumour tissues were performed t...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ströbel, P, Bargou, R, Wolff, A, Spitzer, D, Manegold, C, Dimitrakopoulou-Strauss, A, Strauss, L, Sauer, C, Mayer, F, Hohenberger, P, Marx, A
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2010
Предметы:
Translational Therapeutics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2906735/
https://ncbi.nlm.nih.gov/pubmed/20571495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605740
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы